Long-term data analysis will expand on previously reported efficacy results from Lumoxiti Phase III trial Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “...

Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...

Preclinical data showcases advancement of its immuno-oncology portfolio across the Company’s three strategic pillars: immune checkpoint inhibitors, tumor antigen targeting and tumor micro-environment...

INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate Pharma ” or the “ Company ”), a French biotechnology company focused on discovering, developing and...

INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq Global Select Market: IPHA) (“ Innate ” or the “ Company ”), a French biotechnology company focused on discovering, developing and...

INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421) (“ Innate Pharma ” or the “ Company ”), a French biotechnology company focused on discovering, developing and commercializing first-in...

INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421) (“ Innate ” or the “ Company ”), a French biotechnology company focused on discovering, developing and commercializing first-in-class...

INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421) (“ Innate ” or the “ Company ”), a French biotechnology company focused on discovering, developing and commercializing first-in-class...

The authors present an updated version of The Cancer-Immunity Cycle 1 , the current intellectual framework for immuno-oncology research and development Article covers the mechanisms by which innate...

IPH5401 dose-escalation study in advanced solid tumors, STELLAR-001, shows manageable safety profile Initiation of two expansion cohorts in non-small cell lung cancer (NSCLC) with secondary resistance...